Cargando…

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation

This investigation was conducted to elucidate whether atractylenolide-I (ATL-1), which is the main component of Atractylodes macrocephala Koidz, can sensitize triple-negative breast cancer (TNBC) cells to paclitaxel and investigate the possible mechanism involved. We discovered that ATL-1 could inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Meng, Li, Xue-Zhen, Zhang, Ming-Xing, Ye, Qian-Yu, Chen, Ying-Xia, Chang, Xu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526898/ https://www.ncbi.nlm.nih.gov/pubmed/34692516 http://dx.doi.org/10.3389/fonc.2021.738534

Ejemplares similares

Atractylenolide-I Sensitizes Human Ovarian Cancer Cells to Paclitaxel by Blocking Activation of TLR4/MyD88-dependent Pathway
por: Huang, Jian-Ming, et al.
Publicado: (2014)

Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27
por: Qiao, Pengfei, et al.
Publicado: (2023)

UPLC-MS/MS of Atractylenolide I, Atractylenolide II, Atractylenolide III, and Atractyloside A in Rat Plasma after Oral Administration of Raw and Wheat Bran-Processed Atractylodis Rhizoma
por: Xu, Shizhao, et al.
Publicado: (2018)

Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Sun, Shanshan, et al.
Publicado: (2021)

Anti-tumor effects of Atractylenolide I on bladder cancer cells
por: Yu, Rui, et al.
Publicado: (2016)

Correction to: Anti-tumor effects of Atractylenolide I on bladder cancer cells
por: Yu, Rui, et al.
Publicado: (2018)

Atractylenolide I inhibits antibiotic-induced dysbiosis of the intestinal microbiome
por: Liu, Penglin, et al.
Publicado: (2021)

Anti-Tumor Effects of Atractylenolide-I on Human Ovarian Cancer Cells
por: Long, Fangyi, et al.
Publicado: (2017)

Neuroprotective Role of Atractylenolide-I in an In Vitro and In Vivo Model of Parkinson’s Disease
por: More, Sandeep, et al.
Publicado: (2017)

Anti-Tumor Activity of Atractylenolide I in Human Colon Adenocarcinoma In Vitro
por: Chan, Ka Woon Karen, et al.
Publicado: (2020)

Low-Intensity Focused Ultrasound Targeted Microbubble Destruction Enhanced Paclitaxel Sensitivity by Decreasing Autophagy in Paclitaxel-Resistant Ovarian Cancer
por: Fan, Gonglin, et al.
Publicado: (2022)

Atractylenolide I Induces Apoptosis and Suppresses Glycolysis by Blocking the JAK2/STAT3 Signaling Pathway in Colorectal Cancer Cells
por: Li, Yanxi, et al.
Publicado: (2020)

Propofol Inhibits Proliferation and Augments the Anti-Tumor Effect of Doxorubicin and Paclitaxel Partly Through Promoting Ferroptosis in Triple-Negative Breast Cancer Cells
por: Sun, Chen, et al.
Publicado: (2022)

A Randomized Pilot Study of Atractylenolide I on Gastric Cancer Cachexia Patients
por: Liu, Yi, et al.
Publicado: (2008)

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib
por: Song, Xiang, et al.
Publicado: (2020)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Atractylenolide III ameliorates spinal cord injury in rats by modulating microglial/macrophage polarization
por: Xue, Meng‐Tong, et al.
Publicado: (2022)

P2X7 receptor involved in antitumor activity of atractylenolide I in human cervical cancer cells
por: Han, Yue, et al.
Publicado: (2022)

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
por: Qiu, Xia, et al.
Publicado: (2022)

Correlation between the Warburg effect and progression of triple-negative breast cancer
por: Liu, Shaojun, et al.
Publicado: (2023)

Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I
por: Zhang, Wan-li, et al.
Publicado: (2019)

Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL‐6 and tumour‐derived extracellular vesicles
por: Fan, Meng, et al.
Publicado: (2022)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

ASMT Regulates Tumor Metastasis Through the Circadian Clock System in Triple-Negative Breast Cancer
por: Xie, FenFen, et al.
Publicado: (2020)

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
por: Sanomachi, Tomomi, et al.
Publicado: (2023)

Caffeine modulates glucocorticoid-induced expression of CTGF in lung epithelial cells and fibroblasts
por: Fehrholz, Markus, et al.
Publicado: (2017)

miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
por: Ninio-Many, Lihi, et al.
Publicado: (2020)

Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2022)

POLD2 is activated by E2F1 to promote triple-negative breast cancer proliferation
por: Zhang, Zhen
Publicado: (2022)

Atractylenolide I inhibited the development of malignant colorectal cancer cells and enhanced oxaliplatin sensitivity through the PDK1-FoxO1 axis
por: Sun, Ye, et al.
Publicado: (2022)

Atractylenolide I alleviates ischemia/reperfusion injury by preserving mitochondrial function and inhibiting caspase-3 activity
por: Sun, Caiqin, et al.
Publicado: (2021)

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer
por: Xu, Tao, et al.
Publicado: (2022)

Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer
por: Li, Meng, et al.
Publicado: (2022)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye, Jun, et al.
Publicado: (2016)

Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer
por: Zheng, Yi-Zi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v9pkm16llhttmmq1429ljn04nu